Roswell Park Comprehensive Cancer Center

Running trials

• Recruiting

  Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial

  NCT07605416· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

  NCT07388524· Phase 3· National Cancer Institute (NCI)· Source

• Not yet recruiting

  Home-Based Respiratory Muscle Training and Aerobic Exercise Programs to Improve Lung Health in Current and Former Cigarette Smokers

  NCT07553819· Roswell Park Cancer Institute· Source

• Not yet recruiting

  Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas

  NCT06202066· Phase 2· Roswell Park Cancer Institute· Source

• Recruiting

  Testing Short-Course Radiation Versus Standard-Course Radiation for Soft Tissue Sarcomas That Need Surgery and Radiation

  NCT07615049· Phase 3· SWOG Cancer Research Network· Source

• Not yet recruiting

  Phase I Trial of Pacritinib in Combination With Venetoclax and Azacitidine for the Treatment of Accelerated and Blast Phase Myeloproliferative Neoplasms

  NCT07679334· Phase 1· Roswell Park Cancer Institute· Source

• Not yet recruiting

  Bispecific CD19/CD20-Targeted Chimeric Antigen Receptor (CAR) Modified T Cells With 4-1BB and Mutated CD28 Costimulatory Domains in Patients With Relapsed or Refractory CD19+ Hematologic Malignancies

  NCT07701889· Phase 1· Roswell Park Cancer Institute· Source

• Recruiting

  Hotspot Stereotactic Ablative Radiotherapy Versus Traditional Stereotactic Ablative Radiotherapy for the Treatment of Early-Stage Non-Small Cell Lung Cancer

  NCT07718672· Phase 2· Roswell Park Cancer Institute· Source

• Recruiting

  Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype

  NCT06863402· Phase 2· Roswell Park Cancer Institute· Source

• Recruiting

  Optimal Defaults Grocery Shopping Intervention to Promote Healthy Diets for Pediatric Cancer Survivors and Their Families

  NCT07901816· Roswell Park Cancer Institute· Source

• Recruiting

  Comparing Two Weight Loss Programs for the Prevention of Kidney Cancer Progression Among Patients With Small Renal Masses on Active Surveillance

  NCT07714018· Roswell Park Cancer Institute· Source

• Not yet recruiting

  Evaluating the Delivery and Effects of THC Vaping Liquids in the Bloodstream

  NCT06334016· Early phase 1· Roswell Park Cancer Institute· Source

• Not yet recruiting

  CIMAvax-EGF With KRAS G12C Inhibitor for the Treatment of Advanced, KRAS G12C Mutated Non Small Cell Lung Cancer

  NCT07543172· Phase 2· Roswell Park Cancer Institute· Source

• Not yet recruiting

  Testing the SurVaxM Vaccine for Lung Cancer Prevention

  NCT07169617· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)

  NCT06917911· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

  NCT07437950· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer

  NCT07489287· Phase 1· Roswell Park Cancer Institute· Source

• Recruiting

  A Study of IDP-001 in Advanced or Metastatic Solid Tumors

  NCT07602842· Phase 1/2· InduPro, Inc.· Source

• Recruiting

  Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia

  NCT07504458· Phase 3· Quetzal Therapeutics· Source

• Recruiting

  Intratumoral N17350 in Advanced Solid Tumors

  NCT07339176· Phase 1/2· Onchilles Pharma Inc· Source

• Not yet recruiting

  The Canopy Cancer Collective Clinical Registry Protocol

  NCT07605702· Canopy Cancer Collective, LLC· Source

• Recruiting

  New York Better Breathing Study

  NCT06869447· Roswell Park Cancer Institute· Source

• Recruiting

  Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma

  NCT07068074· Phase 3· ECOG-ACRIN Cancer Research Group· Source

• Recruiting

  GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer

  NCT07017829· Phase 2· Roswell Park Cancer Institute· Source

• Recruiting

  Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial

  NCT07200830· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Recruiting

  Brief Title Mechanisms of Cancer-Related Pain and Opioid Use Among Adolescents and Young Adult Sarcoma Survivors: Pilot Feasibility Study

  NCT07402577· Roswell Park Cancer Institute· Source

• Recruiting

  Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer

  NCT06434064· Phase 2· Roswell Park Cancer Institute· Source

• Recruiting

  A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

  NCT07409272· Phase 3· Astellas Pharma Global Development, Inc.· Source

• Recruiting

  Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma

  NCT07214298· Phase 1/2· Roswell Park Cancer Institute· Source

• Recruiting

  Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes

  NCT07194044· Phase 1· H. Lee Moffitt Cancer Center and Research Institute· Source

• Recruiting

  A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer

  NCT07325136· Phase 1/2· Bristol-Myers Squibb· Source

• Recruiting

  Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

  NCT06871410· Phase 1· Roswell Park Cancer Institute· Source

• Recruiting

  This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma

  NCT07121946· Phase 1· LTZ Therapeutics, Inc.· Source

• Recruiting

  A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement

  NCT06728410· Phase 2· Mehmet Akce· Source

• Recruiting

  A Cruciferous Vegetable Eating Program for the Reduction of Cancer Recurrence and Progression in Patients With Non-muscle Invasive Bladder Cancer

  NCT06733363· Phase 2· Roswell Park Cancer Institute· Source

• Recruiting

  A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

  NCT07188558· Phase 3· Lyell Immunopharma, Inc.· Source

• Recruiting

  Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial

  NCT06995508· Phase 2· Roswell Park Cancer Institute· Source

• Recruiting

  A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

  NCT06524544· Phase 3· National Cancer Institute (NCI)· Source

• Recruiting

  Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

  NCT06931340· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Recruiting

  Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

  NCT06769126· Phase 2· SWOG Cancer Research Network· Source

• Recruiting

  Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

  NCT07061977· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

  NCT07076121· Phase 2/3· Bristol-Myers Squibb· Source

• Recruiting

  A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer

  NCT07027514· Phase 1· Ankyra Therapeutics, Inc· Source

• Recruiting

  A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

  NCT07213804· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

  NCT06649812· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  A Financial Intervention (Financial Compass) to Identify and Address Financial Hardship Among Head and Neck Cancer Patients, Financial Compass Trial

  NCT06896695· Roswell Park Cancer Institute· Source

• Recruiting

  Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

  NCT06958328· Phase 3· NRG Oncology· Source

• Active, not recruiting

  Text Message and Mail Delivery of Tailored Educational Materials to Improve Access to Resources for Smoking Cessation of Menthol Tobacco Cigarettes

  NCT07857681· Roswell Park Cancer Institute· Source

• Recruiting

  A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors

  NCT06997029· Phase 1· Bristol-Myers Squibb· Source

• Recruiting

  Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

  NCT06943755· Phase 2/3· Exelixis· Source

Showing 50 of 440.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers37 recruiting
• Lung cancer29 recruiting
• Acute myeloid leukaemia23 recruiting
• Ovarian cancer13 recruiting
• Acute lymphoblastic leukaemia11 recruiting
• Multiple myeloma11 recruiting
• Sarcoma11 recruiting
• Head and neck cancer9 recruiting
• Metastatic breast cancer9 recruiting
• Myelodysplastic syndromes9 recruiting
• Diffuse large B-cell lymphoma8 recruiting
• Pancreatic cancer8 recruiting
• Prostate cancer8 recruiting
• Triple-negative breast cancer8 recruiting
• Chronic lymphocytic leukaemia7 recruiting
• Colorectal cancer7 recruiting
• Melanoma7 recruiting
• Endometrial cancer6 recruiting
• Kidney cancer6 recruiting
• Bladder cancer5 recruiting
• Chronic myeloid leukaemia5 recruiting
• Gastric and oesophageal cancer5 recruiting
• Myeloproliferative neoplasms5 recruiting
• Follicular lymphoma4 recruiting
• Mantle cell lymphoma4 recruiting
• Hodgkin lymphoma3 recruiting
• Liver and biliary tract cancer3 recruiting
• Neuroendocrine tumours3 recruiting
• Cervical cancer2 recruiting
• Neuroblastoma2 recruiting
• Amyloidosis1 recruiting
• ANCA-associated vasculitis1 recruiting
• Aplastic anaemia1 recruiting
• Brain metastases1 recruiting
• Burkitt lymphoma1 recruiting
• Dermatomyositis and polymyositis (myositis)1 recruiting
• Down syndrome1 recruiting
• Hearing loss1 recruiting
• Lupus (SLE)1 recruiting
• Neurofibromatosis type 11 recruiting
• Obesity1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting

Closed trials

• Withdrawn

  Transperineal Micro-ultrasound for the Detection of Prostate Cancer During Biopsy

  NCT07075705· Roswell Park Cancer Institute· Source

• Withdrawn

  Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung Cancer

  NCT06943664· Phase 2· Roswell Park Cancer Institute· Source

• Withdrawn

  Propranolol Plus Standard Radiation Therapy Before Surgery for the Treatment of Patients With Soft Tissue Sarcoma

  NCT06670976· Phase 1· Roswell Park Cancer Institute· Source

• Withdrawn

  Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma

  NCT07082270· Phase 1· Roswell Park Cancer Institute· Source

• Withdrawn

  FL118 for Treating Patients With Advanced Pancreatic Ductal Adenocarcinoma

  NCT06206876· Phase 1· Roswell Park Cancer Institute· Source

• Recruiting

  Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

  NCT06824168· Phase 2· Daiichi Sankyo· Source

• Terminated

  A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer

  NCT07030907· Phase 1· Outpace Bio, Inc.· Source

• Terminated

  A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer

  NCT06878248· Phase 1· Calibr, a division of Scripps Research· Source

• Withdrawn

  Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer

  NCT05539365· Phase 2· Roswell Park Cancer Institute· Source

• Terminated

  Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies

  NCT06343376· Phase 1· Roswell Park Cancer Institute· Source

• Terminated

  Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma

  NCT04093323· Phase 2· Roswell Park Cancer Institute· Source

• Withdrawn

  Pembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC)

  NCT05518032· Phase 2· Roswell Park Cancer Institute· Source

• Recruiting

  Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer

  NCT05741164· Phase 2· Emory University· Source

• Terminated

  A Study of ASP1012 in Adults With Solid Tumors

  NCT06171178· Phase 1· Astellas Pharma Global Development, Inc.· Source

• Terminated

  Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway

  NCT06287463· Phase 1· Deciphera Pharmaceuticals, LLC· Source

• Completed

  Weight Loss Interventions to Reduce Cancer Progression in Prostate Cancer Patients Under Active Surveillance

  NCT05764330· Roswell Park Cancer Institute· Source

• Terminated

  Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants

  NCT06566092· Phase 1· Iovance Biotherapeutics, Inc.· Source

• Terminated

  Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer

  NCT05756166· Phase 1/2· Roswell Park Cancer Institute· Source

• Withdrawn

  Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic Cancer

  NCT04870034· Early phase 1· Roswell Park Cancer Institute· Source

• Recruiting

  A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes

  NCT06146257· Phase 1· GluBio Therapeutics Inc.· Source

• Withdrawn

  Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

  NCT03735589· Phase 1/2· Roswell Park Cancer Institute· Source

• Recruiting

  Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma

  NCT05874414· Phase 1/2· Genfit· Source

• Completed

  A Phase 1 Study of BMF-500 in Adults With Acute Leukemia

  NCT05918692· Phase 1· Biomea Fusion Inc.· Source

• Completed

  A Virtual Intervention to Improve Medication Adherence in Pediatric Cancer: MedSupport

  NCT05150028· Roswell Park Cancer Institute· Source

• Withdrawn

  A Cytomegalovirus-Directed Vaccine (CMV-alphaDC1) for Preventing Cytomegalovirus Infection or Reactivation in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

  NCT05589844· Phase 1· Roswell Park Cancer Institute· Source

• Terminated

  A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms

  NCT05787496· Phase 1· NextCure, Inc.· Source

• Terminated

  A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202)

  NCT05600426· Phase 3· Boston Children's Hospital· Source

• Terminated

  Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer

  NCT05631574· Phase 1· Biomea Fusion Inc.· Source

• Terminated

  Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET

  NCT05420636· Phase 2· Fox Chase Cancer Center· Source

• Recruiting

  Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

  NCT05633654· Phase 3· Gilead Sciences· Source

• Terminated

  AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer

  NCT05617755· Phase 1· Arsenal Biosciences, Inc.· Source

• Terminated

  SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation

  NCT05375084· Phase 1· Navire Pharma Inc., a BridgeBio company· Source

• Completed

  A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)

  NCT05508867· Phase 2· Merck Sharp & Dohme LLC· Source

• Terminated

  A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors

  NCT05572684· Phase 1/2· NextCure, Inc.· Source

• Completed

  Behavioral Parenting Skills As A Novel Target for Improving Pediatric Medication Adherence

  NCT05587582· Roswell Park Cancer Institute· Source

• Terminated

  Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events

  NCT05224661· Center for International Blood and Marrow Transplant Research· Source

• Completed

  Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002)

  NCT05446870· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  A Sugar-Sweetened Beverage Reduction Intervention for Native American Men

  NCT06029517· Roswell Park Cancer Institute· Source

• Terminated

  Functional Near-Infrared Spectroscopy and Virtual Reality Relaxation Programs for Pain Management in Patients With Cancer

  NCT06456411· Roswell Park Cancer Institute· Source

• Terminated

  Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA

  NCT05245071· Phase 2· Sanofi· Source

• Completed

  Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904)

  NCT04965597· Phase 2· Fred Hutchinson Cancer Center· Source

• Terminated

  Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant

  NCT05305040· Phase 2/3· AlloVir· Source

• Terminated

  Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML

  NCT05275439· Phase 1· Shattuck Labs, Inc.· Source

• Recruiting

  GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC

  NCT04864054· Phase 1/2· Eureka Therapeutics Inc.· Source

• Terminated

  Photodynamic Therapy to Amplify the Response to Immunotherapy in Patients With Non-small Cell Lung Cancer With Pleural Disease

  NCT04836429· Phase 1· Roswell Park Cancer Institute· Source

• Completed

  Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)

  NCT05103358· Phase 2· Aadi Bioscience, Inc.· Source

• Completed

  Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)

  NCT05259696· Phase 1/2· Palleon Pharmaceuticals, Inc.· Source

• Withdrawn

  Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal Cancer

  NCT04119830· Phase 2· Roswell Park Cancer Institute· Source

• Terminated

  Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer

  NCT05037500· Phase 1· Roswell Park Cancer Institute· Source

• Completed

  Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma

  NCT05032820· Phase 2· Medical College of Wisconsin· Source

Showing 50 of 198.

Conditions

Diseases this institution publishes on or runs trials for.

• Prostate cancer59 works · 38 trials
• Multiple myeloma47 works · 35 trials
• Hodgkin lymphoma45 works · 10 trials
• Melanoma42 works · 38 trials
• Triple-negative breast cancer41 works · 22 trials
• Kidney cancer38 works · 37 trials
• Ovarian cancer37 works · 53 trials
• Pancreatic cancer34 works · 29 trials
• Acute myeloid leukaemia32 works · 67 trials
• Bladder cancer30 works · 31 trials
• Acute lymphoblastic leukaemia20 works · 47 trials
• Myelodysplastic syndromes19 works · 28 trials
• Neuroendocrine tumours14 works · 13 trials
• Metastatic breast cancer13 works · 21 trials
• Brain metastases13 works · 4 trials
• Down syndrome9 works · 3 trials
• Follicular lymphoma6 works · 17 trials
• Mesothelioma6 works · 4 trials
• Myeloproliferative neoplasms6 works · 16 trials
• Mantle cell lymphoma6 works · 13 trials
• Gastroparesis5 works · 0 trials
• Haemophagocytic lymphohistiocytosis3 works · 0 trials
• Neurofibromatosis type 13 works · 3 trials
• Trigeminal neuralgia3 works · 0 trials